Reuters logo
BRIEF-Caligor Opco says will support Puma Biotechnology's expanded access program for PB272 (neratinib) in U.S.
April 12, 2017 / 2:46 PM / 8 months ago

BRIEF-Caligor Opco says will support Puma Biotechnology's expanded access program for PB272 (neratinib) in U.S.

April 12 (Reuters) - Caligor Opco LLC:

* To support Puma Biotechnology’s expanded access program for PB272 (neratinib) in United States

* Also is providing regulatory, logistical, supply chain support for Puma’s Managed Access Program for neratinib outside United States Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below